IRIS
GOBBI, MARCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 29.050
AS - Asia 2.649
NA - Nord America 1.502
SA - Sud America 219
AF - Africa 27
OC - Oceania 7
Totale 33.454
Salva come PNG Salva come JPEG
Nazione #
IT - Italia 28.541
US - Stati Uniti d'America 1.406
SG - Singapore 1.189
CN - Cina 716
VN - Vietnam 393
FR - Francia 232
BR - Brasile 144
BD - Bangladesh 118
FI - Finlandia 85
HK - Hong Kong 75
DE - Germania 47
CH - Svizzera 43
CA - Canada 42
AR - Argentina 30
JP - Giappone 30
MX - Messico 24
GB - Regno Unito 20
IN - India 19
IQ - Iraq 19
EC - Ecuador 17
ID - Indonesia 12
UA - Ucraina 12
NL - Olanda 11
ES - Italia 9
RU - Federazione Russa 9
TR - Turchia 9
PH - Filippine 8
TW - Taiwan 8
MA - Marocco 7
PK - Pakistan 7
SA - Arabia Saudita 7
CO - Colombia 6
PL - Polonia 6
PY - Paraguay 6
VE - Venezuela 6
AU - Australia 5
CL - Cile 5
HN - Honduras 5
IE - Irlanda 5
UZ - Uzbekistan 5
ZA - Sudafrica 5
AZ - Azerbaigian 4
CR - Costa Rica 4
DZ - Algeria 4
GT - Guatemala 4
NI - Nicaragua 4
PT - Portogallo 4
TH - Thailandia 4
AE - Emirati Arabi Uniti 3
ET - Etiopia 3
GR - Grecia 3
JM - Giamaica 3
JO - Giordania 3
KR - Corea 3
SV - El Salvador 3
AT - Austria 2
DK - Danimarca 2
HR - Croazia 2
IL - Israele 2
IR - Iran 2
KE - Kenya 2
MM - Myanmar 2
MT - Malta 2
MY - Malesia 2
NO - Norvegia 2
PE - Perù 2
PR - Porto Rico 2
QA - Qatar 2
RO - Romania 2
RS - Serbia 2
SY - Repubblica araba siriana 2
TT - Trinidad e Tobago 2
UY - Uruguay 2
AL - Albania 1
AO - Angola 1
BB - Barbados 1
BE - Belgio 1
BG - Bulgaria 1
CY - Cipro 1
CZ - Repubblica Ceca 1
DO - Repubblica Dominicana 1
EE - Estonia 1
EG - Egitto 1
GF - Guiana Francese 1
KH - Cambogia 1
KW - Kuwait 1
KZ - Kazakistan 1
LV - Lettonia 1
MK - Macedonia 1
MZ - Mozambico 1
NC - Nuova Caledonia 1
OM - Oman 1
PA - Panama 1
PF - Polinesia Francese 1
SE - Svezia 1
SI - Slovenia 1
SN - Senegal 1
TN - Tunisia 1
TZ - Tanzania 1
Totale 33.454
Salva come PNG Salva come JPEG
Città #
Genova 18.691
Genoa 5.876
Rapallo 2.346
Vado Ligure 1.426
San Jose 574
Singapore 537
Lauterbourg 214
Ashburn 129
New York 110
Ho Chi Minh City 104
Helsinki 85
Hanoi 81
Beijing 80
Hong Kong 71
Bordighera 56
Santa Clara 48
Frankfurt am Main 43
Zurich 43
Los Angeles 28
Tokyo 24
Montreal 18
Tianjin 18
Dallas 17
Haiphong 17
Council Bluffs 16
São Paulo 16
Da Nang 15
Atlanta 14
Rome 14
Chicago 13
Mexico City 13
Milan 12
Orem 12
Amsterdam 11
Columbus 11
Phoenix 11
Buffalo 10
Toronto 10
Biên Hòa 9
Naples 9
Chennai 8
Quito 8
Belo Horizonte 7
Can Tho 7
Cardiff 7
Paris 7
Baghdad 6
Boardman 6
Kyiv 6
Madrid 6
Turin 6
Des Moines 5
Quảng Ngãi 5
Warsaw 5
Baku 4
Bắc Giang 4
Charlotte 4
City of London 4
Curitiba 4
Denver 4
Detroit 4
Dublin 4
Guangzhou 4
Guatemala City 4
Guayaquil 4
Hải Dương 4
London 4
Newark 4
Ninh Bình 4
Palermo 4
Perugia 4
Phủ Lý 4
Rio de Janeiro 4
San Juan 4
Shenzhen 4
Tashkent 4
Thái Bình 4
Vĩnh Tường 4
Amman 3
Asunción 3
Austin 3
Bandung 3
Brooklyn 3
Buenos Aires 3
Bình Dương 3
Bắc Ninh 3
Campinas 3
Catania 3
Changsha 3
Cincinnati 3
Florence 3
Guarulhos 3
Johannesburg 3
Las Vegas 3
Lisbon 3
Managua 3
Manchester 3
Marseille 3
Medina 3
Melbourne 3
Totale 31.083
Salva come PNG Salva come JPEG
Nome #
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. 455
APO866 increases antitumor activity of cyclosporin - A by inducing mitochondrial and endoplasmic reticulum stress in leukemia cells 317
APO866 activity in hematologic malignancies: a preclinical in vitro study. 247
Depletion of SIRT6 enzymatic activity increases acute myeloid leukemia cells vulnerability to DNA-damaging agents 244
Unmanipulated haploidentical transplants compared with other alternative donors and matched sibling grafts 239
Age and comorbidities deeply impact on clinical outcome of patients with myelodysplastic syndromes 224
A simple cytofluorimetric score may optimize testing for biallelic CEBPA mutations in patients with acute myeloid leukemia 221
High feasibility and antileukemic efficacy of fludarabine, cytarabine, and idarubicin (FLAI) induction followed by risk-oriented consolidation: A critical review of a 10-year, single-center experience in younger, non M3 AML patients 215
Allogeneic bone marrow transplantation (BMT) for adults with acute lymphoblastic leukemia (ALL): predictive role of minimal residual disease monitoring on relapse 213
A blastic plasmacytoid dendritic cell neoplasm-like phenotype identifies a subgroup of npm1-mutated acute myeloid leukemia patients with worse prognosis 211
Dexamethasone, oxaliplatin and cytarabine (R-DHAOx) as salvage and stem cells mobilizing therapy in relapsed/refractory diffuse large B cell lymphomas 205
Adding low-dose gemtuzumab ozogamicin to fludarabine, Ara-C and idarubicin (MY-FLAI) may improve disease-free and overall survival in elderly patients with non-M3 acute myeloid leukaemia: results of a prospective, pilot, multi-centre trial and comparison with a historical cohort of patients 203
Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives 200
A case of Cunninghamella bertholettiae rhino-cerebral infection in a leukaemic patient and review of recent published studies 198
Direct intrabone transplant of unrelated cord-blood cells in acute leukaemia: a phase I/II study 196
Combined assessment of WT1 and BAALC gene expression at diagnosis may improve leukemia-free survival prediction in patients with myelodysplastic syndromes 195
M-2 protocol for melphalan-resistant and relapsing multiple myeloma. 194
High-dose chemotherapy with tandem autologous transplantation as part of the initial therapy for aggressive non-Hodgkin's lymphoma 193
Combining flow cytometry and WT1 assessment improves the prognostic value of pre-transplant minimal residual disease in acute myeloid leukemia 192
ANTITUMOR ACTIVITY OF NAMPT INHIBITION AND SYNERGY WITH CYCLOSPORIN A AND HDACIS TO PROMOTE APOPTOSIS IN PRIMARY LEUKEMIC CELLS 192
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ). 189
Comparative effects of three cytokine regimens after high-dose cyclophosphamide: granulocyte colony-stimulating factor, granulocyte-macrophage colony-stimulating factor (GM-CSF), and sequential interleukin-3 and GM-CSF 189
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells. 188
Pegfilgrastim compared with filgrastim after autologous peripheral blood stem cell transplantation in patients with solid tumours and lymphomas. 187
Randomized trial of Fludarabine versus fludarabine and Idarubicin as Frontline treatment in patients with indolent or mantle-cell lymphoma 182
Early minimal residual disease assessment after AML induction with fludarabine, cytarabine and idarubicin (FLAI) provides the most useful prognostic information 181
Systematic review of purine analog treatment for chronic lymphocytic leukemia: lessons for future trials. 178
Aminobisphosphonates prevent the inhibitory effects exerted by lymph node stromal cells on anti-tumor V? 2 T lymphocytes in non-Hodgkin lymphomas 178
Hedgehog Signaling Is Useful as a Novel Molecular Marker for Predicting Relapse and Resistance During Chronic Myeloid Leukemia Treatment 177
Evaluating treatment response of chronic myeloid leukemia: emerging science and technology. 177
Combination of liposomal daunorubicin (DaunoXome), fludarabine, and cytarabine (FLAD) in patients with poor-risk acute leukemia. 173
Synergistic interactions between HDAC and sirtuin inhibitors in human leukemia cells 173
Three-step high-dose sequential chemotherapy in patients with newly diagnosed multiple myeloma 172
The new small tyrosine-kinase inhibitor ARQ531 targets acute myeloid leukemia cells by disrupting multiple tumor-addicted programs 172
International randomized phase III study of elacytarabine versus investigator choice in patients with relapsed/refractory acute myeloid leukemia. 171
De novo AML patients with favourable-intermediate karyotype may benefit from the addition of low-dose gemtuzumab ozogamicin (GO) to fludarabine, Ara-C and idarubicin (FLAI): a contribution to the reopened "GO question". 171
High ERp5/ADAM10 expression in lymph node microenvironment and impaired NKG2D ligands recognition in Hodgkin lymphomas. 171
Performance of serum (1,3)-ß-d-glucan screening for the diagnosis of invasive aspergillosis in neutropenic patients with haematological malignancies 171
An immunotoxin containing a rat IgM monoclonal antibody (Campath 1) and saporin 6: effect on T lymphocytes and hemopoietic cells. 170
Liposomal daunorubicin (DaunoXome) for treatment of poor-risk acute leukemia 168
First line therapy with Fludarabine combinations in 42 patients with either post-myelodysplastic syndrome or therapy related acute myeloid leukaemia. 168
Effective in vivo induction of NKG2D ligands in acute myeloid leukaemias by all-trans-retinoic acid or sodium valproate. 166
Evidence for killing of Mesenchymal Stem Cells (MSC) by autologous natural killer lymphocytes. 166
Role of genotype-based approach in the clinical management of adult acute myeloid leukemia with normal cytogenetics. 165
[Allogeneic bone marrow transplantation in multiple myeloma]. 165
A simple prognostic scoring system for newly diagnosed cytogenetically normal acute myeloid leukemia: retrospective analysis of 530 patients. 164
Combination of liposomal Daunorubicin, Fludarabine, and Cytarabine (FLAD) in patients with poor- risk acute leukemia. 163
T lymphocyte subsets and colony growth in hairy-cell leukemia. 163
Alpha-interferon as induction and maintenance therapy in hairy cell leukemia: a long-term follow-up analysis 162
Exploiting tumor vulnerabilities: NAD+-depleting agents combined with anti-tumor drugs as innovative strategy to treat hematological malignancies 161
Bendamustine, etoposide, cytarabine, melphalan, and autologous stem cell rescue produce a 72% 3-year PFS in resistant lymphoma. 160
Tracking molecular relapse of chronic myeloid leukemia by measuring Hedgehog signaling status 160
Thalidomide in agnogenic and secondary myelofibrosis 159
IL4 production and increased CD30 expression by a unique CD8+ T-cell subset in B-cell chronic lymphocytic leukaemia 158
An immunotoxin containing momordin suitable for bone marrow purging in multiple myeloma patients. 158
Quality of life and brain function following high-dose recombinant human erythropoietin in low-risk myelodysplastic syndromes: a preliminary report 157
An immunotoxin made up with campath 1 and saporin 6: preliminary "in vitro" experience. 157
Ber-H2 (anti-CD30)-saporin immunotoxin: a new tool for the treatment of Hodgkin's disease and CD30+ lymphoma: in vitro evaluation. 156
Anaplastic large cell lymphoma: a clinicopathologic study of 53 patients. 155
Complex structural involvement of chromosome 7 in primary myelodysplastic syndromes determined by fluorescence in situ hybridization. 155
An Epstein-Barr virus-infected lymphoblastoid cell line (D430B) grows in SCID-mice with the features of a CD30+ anaplastic large cell lymphoma and is sensitive to anti-CD30 immunotoxins 154
HIV-related malignant lymphoma: a report of 46 cases observed in Italy. 154
First line Fludarabine treatment of symptomatic chronic lymphoproliferative diseases: clinical results and molecular analysis of minimal residual disease 153
Phorbol ester induces abnormal chronic lymphocytic leukemia cells to express features of hairy cell leukemia. 153
Differences among young adults, adults and elderly chronic myeloid leukemia patients. 153
A comparison of anti-lymphocyte immunotoxins containing different ribosome-inactivating proteins and antibodies. 152
Immunohistochemical detection of the multidrug transport protein P170 in human normal tissues and malignant lymphomas. 151
Prognostic relevance of tumour-cell growth fraction in malignant non-Hodgkin's lymphomas. 151
Targeting of a plasma cell line with a conjugate containing xanthine oxidase and the monoclonal antibody 62B1. 151
Molecular analysis of the Imatinib-induced complete cytogenetic response in chronic myelogenous leukemia 150
HDAC INHIBITORS SYNERGISTICALLY ENHANCE AP0866 ACTIVITY IN HUMAN LEUKEMIA CELLS: EVIDENCE FOR CONVERGING MECHANISMS OF SIRT1 INHIBITION 150
New insights into biology of chronic myeloid leukemia: implications in therapy. 150
A T315I mutation in e19a2 BCR/ABL1 chronic myeloid leukemia responding to dasatinib 150
Targeting NAD(+) Salvage Pathway Induces Autophagy in Multiple Myeloma Cells 149
Role of liposomal daunorubicin, fludarabine and cytarabine (FLAD) in the salvage therapy of adult acute lymphoblastic leukemia 149
An unusual reaction to alpha interferon in a case of non Hodgkin's lymphoma. 148
Hodgkin's disease (HD): a historical perspective. 148
Rituximab efficacy in CIDP associated with idiopathic thrombocytopenic purpura 148
Leukocyte-associated Ig-like receptor-1 prevents granulocyte-monocyte colony stimulating factor-dependent proliferation and Akt1/PKB alpha activation in primary acute myeloid leukemia cells 147
Epigenetic regulation of nuclear PI-PLCbeta1 signaling pathway in low-risk MDS patients during azacitidine treatment. 147
Vimentin and keratin intermediate filaments expression by K562 leukemic cell line. 147
Haploientical Transplants with Post-Transplant Cyclophosphamide for Relapsed or Refractory Hodgkin Lymphoma: The Role of Comorbidity Index and Pretransplant Positron Emission Tomography 147
Fludarabine in untreated and previously treated B-CLL patients: a report on efficacy and toxicity. 145
Kinase domain mutations of BCR-ABL identified at diagnosis before imatinib-based therapy are associated with progression in patients with high Sokal risk chronic phase chronic myeloid leukemia. 145
Targeting NAD+ Salvage Pathway Induces Autophagy in Multiple Myeloma Cells via mTORC1 and Extracellular Signal-Regulated Kinase (ERK1/2) Inhibition 144
Immunocytochemical evaluation of the percentage of proliferating cells in pathological bone marrow and peripheral blood samples with the Ki-67 and anti-bromo-deoxyuridine monoclonal antibodies. 144
Therapy of Hodgkin's lymphoma in clinical practice: A retrospective long-term follow-up analysis. 144
Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: A feasible and effective salvage treatment for lymphoid malignancies 144
Four-step high-dose sequential chemotherapy with double hematopoietic progenitor cell rescue for metastatic breast cancer 143
Autologous bone marrow transplantation with immunotoxin-purged marrow for advanced multiple myeloma 142
CEOP regimen in the treatment of advanced low-grade non-Hodgkin's lymphomas: preliminary report. 142
Normal equivalent cells of B cell malignancies: analysis with monoclonal antibodies. 142
New insights into the treatment of multiple myeloma with histone deacetylase inhibitors. 142
Donor lymphocyte infusions for the treatment of minimal residual disease in acute leukemia 142
Fludarabine, ARA-C, idarubicin and G-CSF (FLAG-Ida), high dose ARA-C and early stem cell transplant. A feasable and effective therapeutic strategy for de novo AML patients. 140
Intracellular NAD⁺ depletion enhances bortezomib-induced anti-myeloma activity. 140
[Methods for studying pleiotropic drug resistance (multidrug resistance, MDR)]. 140
Long-lasting effect of cyclosporin-A on anemia associated with idiopathic myelofibrosis. 139
Laparoscopic splenectomy for hematological diseases. 139
Multimarker phenotypic characterization of adult and childhood acute lymphoblastic leukaemia: an Italian multicentre study. 139
Totale 17.168
Salva come PNG Salva come JPEG
Categoria #
all - tutte 95.605
article - articoli 94.451
book - libri 0
conference - conferenze 285
curatela - curatele 0
other - altro 370
patent - brevetti 0
selected - selezionate 0
volume - volumi 499
Totale 191.210
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021154 0 0 0 0 0 0 0 0 0 0 0 154
2021/20222.848 78 210 206 293 174 180 158 679 93 295 98 384
2022/20232.839 306 163 38 272 506 554 11 235 470 35 211 38
2023/20241.387 68 189 33 143 128 295 61 128 64 21 76 181
2024/20253.710 67 327 114 227 450 347 346 596 105 155 460 516
2025/20266.834 851 163 323 663 811 753 1.186 332 540 637 387 188
Totale 33.669